Bioanalytical LC-MS/MS Method Development and Validation of Novel Antidiabetic Candidate S007-1261 in Rat Plasma and its Application to Pharmacokinetic and Oral Bioavailability Studies

A. Misra; H. N. Kushwaha; N. Gautam; B. Singh; P. C. Verma; R. Pratap; S. K. Singh

doi:10.1055/s-0033-1358739

Drug Research, Table of Contents

Drug Res (Stuttg) 2014; 64(08): 399-405
DOI: 10.1055/s-0033-1358739

Original Article

Bioanalytical LC-MS/MS Method Development and Validation of Novel Antidiabetic Candidate S007-1261 in Rat Plasma and its Application to Pharmacokinetic and Oral Bioavailability Studies

A. Misra

¹Pharmacokinetics and Metabolism Division, CSIR-Central Drug Research Institute, Lucknow, India

,

H. N. Kushwaha

¹Pharmacokinetics and Metabolism Division, CSIR-Central Drug Research Institute, Lucknow, India

,

N. Gautam

¹Pharmacokinetics and Metabolism Division, CSIR-Central Drug Research Institute, Lucknow, India

,

B. Singh

¹Pharmacokinetics and Metabolism Division, CSIR-Central Drug Research Institute, Lucknow, India

,

P. C. Verma

²Medicinal and Process Chemistry Division, CSIR-Central Drug Research Institute, Lucknow, India

,

R. Pratap

²Medicinal and Process Chemistry Division, CSIR-Central Drug Research Institute, Lucknow, India

,

S. K. Singh

¹Pharmacokinetics and Metabolism Division, CSIR-Central Drug Research Institute, Lucknow, India

› Author Affiliations

Abstract

A sensitive and selective LC-MS/MS method has been developed and validated for CDRI antidiabetic candidate S007-1261 in rat plasma using 16-dehydropregnenolone as an internal standard. The API 4000 triple quadrupole LC-MS/MS system was operated under multiple reaction monitoring mode using electrospray ionization technique in positive mode. The sample processing method involves 2-step liquid-liquid extraction using n-hexane as an extracting solvent. The analyte was chromatographed on RP 18, waters column (3.5 µm, 2.1 mm i.d.×30 mm) with guard using acetonitrile and ammonium acetate buffer (pH 5.0, 10 mM) in 90:10 (v/v) composition at a flow rate of 0.40 mL min⁻¹. The chromatographic run time was 5.30 min. Calibration curve shows linearity over concentration range 1.56–200 ng mL⁻¹. The lower limit of detection was 0.39 ng mL⁻¹ and lower limit of quantitation was 1.56 ng mL⁻¹. The inter- and intra-day accuracy and precision were found to be within the assay variability limits as per US FDA guidelines. The absolute recovery of S007-1261 was found to be >90%. S007-1261 does not show any stability problems as it was stable at room temperature for 8 h. S007-1261 was also stable up to 3 freeze-thaw cycles and can be stored up to 30 days at −60°C. The assay was successfully applied to both oral (40 mg kg⁻¹) and intravenous (10 mg kg⁻¹) pharmacokinetic studies in male Sprague-Dawley rats. The oral bioavailability of S007-1261 was found to be 33.61%.

Key words

antidiabetic - LC-MS/MS - S007-1261 - pharmacokinetics - rat plasma

Full Text

References

References
1 Mandrup-Poulsen T. Recent Advances: Diabetes. Br Med J 1998; 316: 1221-1225
2 Henry R, Robert MD. Glucose control and insulin resistance in non-insulin-dependent diabetes mellitus. Ann Intern Med 1996; 124: 97-103
3 van de Laar FA, Lucassen PL, Akkermans RP et al. Alpha-glucosidase inhibitors for patients with type 2 diabetes: Results from a Cochrane systematic review and meta-analysis. Diabetes Care 2005; 28: 154-163
4 Bolen S, Feldman L, Vassy J et al. Systematic review: Comparative effectiveness and safety of oral medication for type 2 diabetes mellitus. Ann Intern Med 2007; 147: 386-399
5 Rendell M. Advances in diabetes for the millennium: Drug therapy of type 2 diabetes. Med Gen Med 2004; 6: 9
6 Scarpello JHB, Howlett H. Metformin therapy and clinical uses. Diab Vasc Dise Res 2008; 5: 157-167
7 Erdmann E, Dormandy JA, Charbonnel B et al. The effect of pioglitazone on recurrent myocardial infarction in 2 445 patients with type 2 diabetes and previous myocardial infarction: Results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 2007; 49: 1772-1780
8 Shah VP, Midha KK, Dighe S et al. Analytical method validation: Bioavailability, bioequivalence and pharmacokinetic studies. Eur J Drug Metab Pharmacokin 1991; 16: 249-255
9 Dams R, Huestis MA, Lambert WE et al. Matrix effect in bio-analysis of illicit drugs with LC-MS/MS: Influence of ionization type, sample preparation and biofluid. J Am Soc Mass Spectrom 2003; 14: 1290-1294
10 Desai A, Lee M. Gibaldi’s drug delivery system in pharmaceutical care. American Society of Health-System Pharmacists 2007; 197-232
11 Strickley RG. Solubilizing excipents in oral and injectable formulations. Pharm Res 2004; 21: 201-230
12 Causon R. Validation of chromatographic methods in biomedical analysis: Viewpoint and discussion. J Chromatogr B 1997; 689: 175-180
13 Suryawanshi S, Singh SK, Gupta RC. A sensitive and selective HPLC/ESI-MS/MS assay for the simultaneous quantification of 16-dehyropregnenolone and its major metabolites in rabbit plasma. J Chromatogr B 2006; 830: 54-63
14 Singh SP, Singh RS Wahajuddin Development and validation of a rapid, sensitive liquid chromatography-tandem mass spectrometery method using electrospray ionization for quantitation of centchroman in rat plasma and its application to preclinical pharmacokinetic study. J Chromatogr B 2008; 876: 1-7
15 Xu W, Zhang YP, Yang M et al. LC-MS/MS method for the simultaneous determination of icariin and its major metabolites in rat plasma. J Pharm BiomedAnal 2007; 45: 667-672
16 Gautam N, Kushwaha HN, Kumar H et al. LC-MS/MS assay for quantification of a novel antidiabetic flavones derivative S007-857 in rat plasma, urine and feces: Application in pharmacokinetic studies. Chromatographia 2011; 73: 905-912
17 Green JM. A practical guide to analytical method validation. Anal Chemi 1996; 68: 305-309
18 Robbie G, Wu TC, Chiou WL. Poor and unusually prolonged oral absorption of amphotericin B in rats. Pharm Res 1999; 16: 455-458